Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped LFG316, had been studied in seven patients with transplantation-associated microangiopathy. Due to low confidence of clinical benefit, this study was closed.

Conditions

Transplant Associated Microangiopathy TAM

Interventions

DRUG: LFG316 active drug
OTHER: Standard of care treatment

Sponsor

Novartis Pharmaceuticals